Validation of diagnostic wearable ECG data from high-risk patients and integration into the atrial fibrillation catheter ablation pathway

Abstract Background Wearables like the Apple Watch (AW) offer non-invasive, long-term monitoring and patient-led, single-lead ECG recordings. Although validated for Atrial Fibrillation (AF) detection in the general population, the accuracy and clinical utility of the single-lead ECG recording feature for the diagnosis of AF has not been evaluated in patients at high risk of atrial arrhythmias.(1) An evaluation of the accuracy of the Wearable-derived labels is important to determine the feasibility of integrating AW-based remote monitoring into clinical pathways. Objective To evaluate the accuracy and data burden from AW-based, patient-led ECG monitoring in patients undergoing AF catheter ablation. Methods Patients referred for first-time AF catheter ablation to the Study Institution between January 2022 and March 2023 were invited to enrol in the AF Follow-up with Apple Watch (AFFU-AW) Trial. Patients randomised to the active arm of the study received 12 months of post-ablation follow-up using a loaned Apple Watch. Participants underwent an education session and were asked to perform daily ECGs; sending through any labelled as AF, inconclusive, or in the context of symptoms. The accuracy of the automated ECG labelling was determined against blinded, independent labelling by two experienced Electrophysiologists. Results 1093 remote transmissions were emailed in for evaluation from 52 patients to the Study team. This was a median of 6 [2, 17] per patient and a receiver burden of 2 [1, 4] ECGs per day. 475 were categorised by the AW as AF with a sensitivity of 0.71 and specificity of 0.96 compared to expert labelling. 342 (31%) were not categorised by the wearable, with an ‘inconclusive’ interpretation (161 [47%]) or ‘high heart rate’ (108 [32%]) as the most cited reasons. 178 (55%) of the uncategorised ECGs were subsequently overread as AF. Accompanying symptoms were reported with 324 (30%) ECGs, most commonly palpitations. Conclusion This is the first reported evaluation of the AF diagnostic feature based on AW ECG recordings as part of a remote patient rhythm surveillance pathway after catheter ablation. The high positive predictive value of ‘Sinus Rhythm’ and ‘AF’ labels and the high specificity of the ‘AF’ label are comparable to diagnostic algorithms in implantable loop recorders.(2) The source code to automate data curation and structured databasing of wearable ECGs has been made available for care providers to integrate the service into device monitoring workflows.(3)

Authors

Institutions

Publication Details

Journal
European Heart Journal
Published
2024-10-01
DOI
https://doi.org/10.1093/eurheartj/ehae666.3421
Citations
1
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Validation of diagnostic wearable ECG data from high-risk patients and integration into the atrial fibrillation catheter ablation pathway

Nikhil Ahluwalia, Charles Butcher, Edd Maclean, Richard J. Schilling et al.
1 citations
European Heart Journal
Atrial Fibrillation Management and Outcomes
0.40
article

Validation of diagnostic wearable ECG data from high-risk patients and integration into the atrial fibrillation catheter ablation pathway

Nikhil Ahluwalia, Charles Butcher, Edd Maclean, Richard J. Schilling, Amir Hussain, G Saengkrajang, H Abbass
article en
1 citations

Abstract

Abstract Background Wearables like the Apple Watch (AW) offer non-invasive, long-term monitoring and patient-led, single-lead ECG recordings. Although validated for Atrial Fibrillation (AF) detection in the general population, the accuracy and clinical utility of the single-lead ECG recording feature for the diagnosis of AF has not been evaluated in patients at high risk of atrial arrhythmias.(1) An evaluation of the accuracy of the Wearable-derived labels is important to determine the feasibility of integrating AW-based remote monitoring into clinical pathways. Objective To evaluate the accuracy and data burden from AW-based, patient-led ECG monitoring in patients undergoing AF catheter ablation. Methods Patients referred for first-time AF catheter ablation to the Study Institution between January 2022 and March 2023 were invited to enrol in the AF Follow-up with Apple Watch (AFFU-AW) Trial. Patients randomised to the active arm of the study received 12 months of post-ablation follow-up using a loaned Apple Watch. Participants underwent an education session and were asked to perform daily ECGs; sending through any labelled as AF, inconclusive, or in the context of symptoms. The accuracy of the automated ECG labelling was determined against blinded, independent labelling by two experienced Electrophysiologists. Results 1093 remote transmissions were emailed in for evaluation from 52 patients to the Study team. This was a median of 6 [2, 17] per patient and a receiver burden of 2 [1, 4] ECGs per day. 475 were categorised by the AW as AF with a sensitivity of 0.71 and specificity of 0.96 compared to expert labelling. 342 (31%) were not categorised by the wearable, with an ‘inconclusive’ interpretation (161 [47%]) or ‘high heart rate’ (108 [32%]) as the most cited reasons. 178 (55%) of the uncategorised ECGs were subsequently overread as AF. Accompanying symptoms were reported with 324 (30%) ECGs, most commonly palpitations. Conclusion This is the first reported evaluation of the AF diagnostic feature based on AW ECG recordings as part of a remote patient rhythm surveillance pathway after catheter ablation. The high positive predictive value of ‘Sinus Rhythm’ and ‘AF’ labels and the high specificity of the ‘AF’ label are comparable to diagnostic algorithms in implantable loop recorders.(2) The source code to automate data curation and structured databasing of wearable ECGs has been made available for care providers to integrate the service into device monitoring workflows.(3)

European Heart JournalVol. 45(Supplement_1)
Queen Mary University of London (GB), British Heart Foundation (GB)
Openalex Percentile: Top 31%
Atrial Fibrillation Management and Outcomes
0.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.